Elizabeth N. Chung 1,2,8, Jinsu Lee 1,2,8, Carolina M. Polonio 1,2, Joshua Choi 1,2, Camilo Faust Akl 1,2, Michael Kilian 1,2, Wiebke M. Weiß 1,2, Georgia Gunner 3, Mingyu Ye 4, Tae Hyun Heo 1,2, Sienna S. Drake 1,2, Liu Yang 1,2, Catarina R. G. L. d’Eca 1,2, Joon-Hyuk Lee 1,2, Liwen Deng 3, Daniel Farrenkopf 1,2, Anton M. Schüle 1,2, Hong-Gyun Lee 1,2, Oreoluwa Afolabi 1,2, Sharmin Ghaznavi 5,6, Stelios M. Smirnakis 4, Isaac M. Chiu 3, Vijay K. Kuchroo 1,2,7, Francisco J. Quintana 1,2,7 & Michael A. Wheeler 1,2,*
1The Gene Lay Institute of Immunology and Inflammation, Brigham and Women’s Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
2Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Boston, MA, USA.
3Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
4Department of Neurology, Brigham and Women’s Hospital and Jamaica Plain Veterans Administration Hospital, Harvard Medical School, Boston, MA, USA.
5Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
6Center for the Neuroscience of Psychedelics, Massachusetts General Hospital, Boston, MA, USA.
7Broad Institute of MIT and Harvard, Cambridge, MA, USA.
8These authors contributed equally: Elizabeth N. Chung, Jinsu Lee
*Corresponding author: correspondence to Michael A. Wheeler